p--benzoesaeure | 5344-07-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p--benzoesaeure
• 英文别名: p-[N-(o-Hydroxy-benzoyl)-amino]-benzoesaeure；P-Salicylamidobenzoic acid；4-[(2-hydroxybenzoyl)amino]benzoic acid
• CAS: 5344-07-0
• 化学式: C₁₄H₁₁NO₄
• mdl: MFCD03544700
• 分子量: 257.246
• InChiKey: IBZSQWHMOFFVEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090

反应信息

• 作为产物：
  描述：

  邻乙酰水杨酰氯 在 sodium hydroxide 、 三乙胺 作用下， 以 乙酸乙酯 为溶剂， 反应 6.0h， 生成 p--benzoesaeure
  参考文献：
  名称：

  4-[4-[(2-Hydroxybenzoyl)amino]phenyl]butyric Acid as a Novel Oral Delivery Agent for Recombinant Human Growth Hormone

  摘要：

  A series of N-acetylated, non-alpha, aromatic amino acids was prepared and shown to promote the absorption of recombinant human growth hormone (rhGH) from the gastrointestinal tract. Seventy compounds in this family were tested in vivo in rats. Of the compounds tested, 4-[4-[(2-hydroxybenzoyl)amino]phenyl]butyric acid was identified as a preclinical candidate and was used to demonstrate the oral delivery of rhGH in primates. A significant positive correlation was found between the relative log k' of the delivery agents, as determined by HPLC on an immobilized artificial membrane (IAM) column, and serum rhGH concentrations following oral or colonic dosing in rats. Structure-activity relationships have also been developed on the basis of electronic effects and hydrogen-bonding characteristics of the aromatic amide substituents.

  DOI：

  10.1021/jm960038f

文献信息

• AZEPANES AND THEIR RING HOMOLOGUES FOR THERAPY AND PROPHYLAXIS OF PROTEIN KINASE MEDIATED DISEASES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0836592A1

  公开（公告）日：1998-04-22
• US5907038A
  申请人：——

  公开号：US5907038A

  公开（公告）日：1999-05-25
• US6136969A
  申请人：——

  公开号：US6136969A

  公开（公告）日：2000-10-24
• [EN] NOVEL AZEPANES AND THEIR RING HOMOLOGUES FOR THERAPY AND PROPHYLAXIS OF PROTEIN KINASE MEDIATED DISEASES<br/>[FR] AZEPANES NOUVEAUX ET LEURS HOMOLOGUES CYCLIQUES POUR LE TRAITEMENT ET LA PROPHYLAXIE DES MALADIES A MEDIATION PAR LA PROTEINE-KINASE
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：WO1997002249A1

  公开（公告）日：1997-01-23

  (EN) Compounds of general formula (I), wherein R1 is phenyl or alpha- or beta- naphthyl, which groups can be substituted by hydroxy, lower-alkyl, lower-alkoxy, lower alkoxy-carbonyl, phenoxy, acyloxy, hydroxyphenoxy-sulfonyl, halogen, nitro, amino, acylamino or N-lower-alkyl-acylamino; R2 is phenyl or phenyl substituted by hydroxy or acyloxy; Y is a carbon-carbon bond or is vinylene; and n is 1, 2 or 3; and pharmaceutically acceptable acid addition salts thereof are protein kinase inhibitors and can be used for the treatment of disorders mediates by such enzymes, e.g., inflammatory diseases.(FR) Les composés de formule générale (I) dans laquelle R1 est phényle ou alpha- ou bêta-naphtyle, ces groupes pouvant être substitués par hydroxy, alkyle inférieur, alcoxy inférieur, alcoxy-carbonyl de faible PM, phénoxy, acyloxy, hydroxyphénoxy-sulfonyle, halogène, nitro, amino, acylamino ou N-alkylacylamino inférieur; R2 est phényle ou phényle substitué par hydroxy ou acyloxy; Y est une liaison carbone-carbone ou est vinylène; et n vaut 1, 2 ou 3; ainsi que leurs sels d'addition acide pharmaceutiquement acceptables, sont des inhibiteurs de la protéine kinase et peuvent être utilisés pour le traitement des troubles dont celle-ci est le médiateur, tels que les maladies inflammatoires.
• 4-[4-[(2-Hydroxybenzoyl)amino]phenyl]butyric Acid as a Novel Oral Delivery Agent for Recombinant Human Growth Hormone
  作者：Andrea Leone-Bay、Koc-Kan Ho、Rajesh Agarwal、Robert A. Baughman、Kiran Chaudhary、Frenel DeMorin、Lise Genoble、Campbell McInnes、Christine Lercara、Sam Milstein、Doris O'Toole、Donald Sarubbi、Bruce Variano、Duncan R. Paton

  DOI：10.1021/jm960038f

  日期：1996.1.1

  A series of N-acetylated, non-alpha, aromatic amino acids was prepared and shown to promote the absorption of recombinant human growth hormone (rhGH) from the gastrointestinal tract. Seventy compounds in this family were tested in vivo in rats. Of the compounds tested, 4-[4-[(2-hydroxybenzoyl)amino]phenyl]butyric acid was identified as a preclinical candidate and was used to demonstrate the oral delivery of rhGH in primates. A significant positive correlation was found between the relative log k' of the delivery agents, as determined by HPLC on an immobilized artificial membrane (IAM) column, and serum rhGH concentrations following oral or colonic dosing in rats. Structure-activity relationships have also been developed on the basis of electronic effects and hydrogen-bonding characteristics of the aromatic amide substituents.